Scholarlink

<p>Clear cell renal cell carcinoma poses unique challenges for immunotherapy, particularly with immune checkpoint inhibitors. Many ccRCC tumors exhibit an “immune-cold” tumor immunosuppressive microenvironment (TIME), characterized by poor T cell infiltration and multiple immunosuppressive barriers, leading to primary or acquired resistance to ICIs. Approaches to convert these tumors into “immune-hot” (T cell–inflamed) states are critical for improving therapeutic outcomes. Nanomedicine offers promising solutions by modulating the broader tumor microenvironment (TME) and enabling precision delivery of immune-modulatory agents. In this review, we highlight how nanotechnology-based platforms can alleviate hypoxia and acidity in the TME, reprogram suppressive myeloid cells within the TIME (e.g., myeloid-derived suppressor cells and tumor-associated macrophages), and synergize with ICIs and targeted therapies. We summarize recent advances in ccRCC and ccRCC-relevant preclinical models, distinguishing direct RCC evidence from hypothesis-generating findings derived from other solid tumors. These integrative nano-immunotherapy approaches aim to overcome immunoresistance in ccRCC, turning immunologically “cold” tumors “hot” and improving the depth and durability of anti-tumor immune responses.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanomedicine-based sensitization and resistance reversal in immunotherapy of clear cell renal cell carcinoma: from tumor microenvironment to precision delivery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Jinhu Ma,
  • Ziyang Qiang,
  • Wenhao Xie,
  • Liang Jiao,
  • Lin Mi,
  • Kai Ma,
  • Zhangjie Yang,
  • Guojun Chen

摘要

Clear cell renal cell carcinoma poses unique challenges for immunotherapy, particularly with immune checkpoint inhibitors. Many ccRCC tumors exhibit an “immune-cold” tumor immunosuppressive microenvironment (TIME), characterized by poor T cell infiltration and multiple immunosuppressive barriers, leading to primary or acquired resistance to ICIs. Approaches to convert these tumors into “immune-hot” (T cell–inflamed) states are critical for improving therapeutic outcomes. Nanomedicine offers promising solutions by modulating the broader tumor microenvironment (TME) and enabling precision delivery of immune-modulatory agents. In this review, we highlight how nanotechnology-based platforms can alleviate hypoxia and acidity in the TME, reprogram suppressive myeloid cells within the TIME (e.g., myeloid-derived suppressor cells and tumor-associated macrophages), and synergize with ICIs and targeted therapies. We summarize recent advances in ccRCC and ccRCC-relevant preclinical models, distinguishing direct RCC evidence from hypothesis-generating findings derived from other solid tumors. These integrative nano-immunotherapy approaches aim to overcome immunoresistance in ccRCC, turning immunologically “cold” tumors “hot” and improving the depth and durability of anti-tumor immune responses.